Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

BACKGROUND: SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The current report presents the PRO results for this trial, an impor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Patient Rep Outcomes
Hlavní autoři: Unger, Joseph M., Griffin, Katherine, Donaldson, Gary W., Baranowski, Karen M., Good, Margorie J., Reburiano, Eunicia, Hussain, Maha, Monk, Paul J., Van Veldhuizen, Peter J., Carducci, Michael A., Higano, Celestia S., Lara, Primo N., Tangen, Catherine M., Quinn, David I., Wade, James L., III, Vogelzang, Nicholas J., Thompson, Ian M., Jr, Moinpour, Carol M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2018
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5997724/
https://ncbi.nlm.nih.gov/pubmed/29951640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41687-018-0054-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky